ABSTRACT
The treatment of heart failure (HF) has advanced greatly in recent decades. Today, based on evidence, it includes beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers and spironolactone. For symptomatic patients, we must add a diuretic and/or digitalis. For these medications to be effective they must be used in full doses. The objective of this study was the correct treatment modifies the natural history of the disease, reducing its morbidity and mortality. To check its effectiveness, symptoms reduction, reversal of, increase of ejection fraction and reduction of heart rate are assessed. When there is no improvement of these characteristics, or the treatment is inadequate and must be improved, or the clinical picture is very serious, there is a poor prognosis. Early detection of HF allows measures to be taken in order to modify the natural history of the disease. Thus, we should encourage the correct treatment since early stages of the disease, preventing progression to advanced and refractory forms.
O tratamento da insuficiência cardíaca (IC) avançou muito nas últimas décadas. Hoje, baseado em evidências inclui o uso de betabloqueadores, inibidores da enzima conversora de angiotensina,bloqueadores do receptor da angiotensina II e espironolactona.Para os pacientes sintomáticos devem-se acrescentar um diurético e/ou digital. Para que esses fármacos sejam efetivos devem ser empregados em doses plenas. O objetivo deste estudo foi observar o tratamento correto modifica a história natural da doença, reduzindo sua morbidade e mortalidade. Para verificar sua efetividade,avalia-se a melhora dos sintomas, reversão da dilatação cardíaca,aumento da fração de ejeção e redução da frequência cardíaca.Quando não há melhora destas características, ou o tratamento é insuficiente e deve ser melhorado ou que o quadro clínico é muito grave e o paciente terá, então, um prognóstico sombrio. A detecção precoce da insuficiência cardíaca permite que medidas sejam tomadas a fim de modificar a história natural da doença.Deve-se, portanto encorajar o tratamento correto desde os estágios iniciais da doença, prevenindo a progressão para formas avançadas e refratárias.
Subject(s)
Humans , Male , Female , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Heart Failure/diagnosis , Heart Failure/prevention & control , Heart Failure/drug therapy , Stroke VolumeABSTRACT
Objective To investigate the effects of Tong Xin-Luo on cultured human umbilical vein endothelial cells (HUVECs) impaired by Lysophosphatidylcholine.Methods The herbage-contained serum of TXL was prepared,HUVECs were cultured in vitro.The study was designated to 4 group:normal control,LPC group,TXL group,and TXL + LPC intervened group.The cell function was determined by cell morphology and MTT colorimetric assay.Results Compaired with normal control group (0.380 ±0.023 ),LPC ( 0.320 ± 0.024 ) could significantly decrease the cells activity,promote cells death ( P ＜0.05 ).After TXL intervened(0.424 ±0.034),cells activity was significantly increased,cells death was d significantly decreased( P ＜0.05 ).Conclusions Tong Xin-Luo could protect human umbilical vein endothelial cells function by against the LPC-induced damage.